GENT logo

Gentian Diagnostics ASA Stock Price

OB:GENT Community·NOK 842.1m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

GENT Share Price Performance

NOK 54.60
12.40 (29.38%)
NOK 67.00
Fair Value
NOK 54.60
12.40 (29.38%)
18.5% undervalued intrinsic discount
NOK 67.00
Fair Value
Price NOK 54.60
AnalystConsensusTarget NOK 67.00

GENT Community Narratives

AnalystConsensusTarget·
Fair Value NOK 67 18.5% undervalued intrinsic discount

Expanding Into $18 Billion Diagnostics Market Will Boost Prospects Despite Potential Risks

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
NOK 67
18.5% undervalued intrinsic discount
Revenue growth
34.44% p.a.
Profit Margin
9.04%
Future PE
34.11x
Share price in 2028
NOK 79.36

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
4 Rewards

Gentian Diagnostics ASA Key Details

NOK 172.5m

Revenue

NOK 77.5m

Cost of Revenue

NOK 95.0m

Gross Profit

NOK 52.2m

Other Expenses

NOK 42.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 11, 2026
2.77
55.06%
24.80%
0%
View Full Analysis

About GENT

Founded
2001
Employees
63
CEO
Matti Heinonen
WebsiteView website
www.gentian.com

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase. In addition, the company provides faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Recent GENT News & Updates

Recent updates

No updates